1. Introduction {#s1}
===============

Percutaneous coronary intervention (PCI) has been widely used in treating elderly patients with coronary artery disease (CAD); clinical studies have confirmed the safety and efficacy of this treatment towards these patients.[@b1]--[@b5] Given the special systemic conditions of elderly CAD patients, as well as the complexity of CAD, their revascularisation strategies and prognosis differ from those of young patients.[@b6] Thus, clinicians should perform accurate risk stratification and prognosis assessment in elderly CAD patients to identify the high-risk group.

As an intrinsic parameter in blood tests, red blood cell distribution width (RDW) was initially only used in the diagnosis and differential diagnosis of anemia. In 2007, Felker, *et al*.[@b7] firstly discovered that increasing RDW is an independent predictor for the prognosis of heart failure patients, and researchers gradually discovered that RDW is closely associated with the prognosis of cardiovascular diseases. Recent studies showed that increasing RDW is not only a predictor for poor prognosis of heart failure,[@b7],[@b8] CAD,[@b9]--[@b11] and pulmonary hypertension,[@b12],[@b13] but it also exhibits a predictive value towards the prognosis of stable CAD patients who have underwent PCI therapy.[@b14],[@b15] As of this writing, research on the effects of RDW on the prognosis of elderly CAD patients after PCI treatment is lacking. Therefore, this study aimed to clarify the relationship between RDW and intermediate-term all-cause mortality of elderly CAD patients after elective PCI therapy.

2. Methods {#s2}
==========

2.1. Study group {#s2a}
----------------

Among 3574 CAD cases who underwent PCI treatment and had preoperative RDW records in the Beijing Anzhen Hospital from July 2009 to September 2011, 1891 patients aged ≥ 65 years old who underwent elective PCI were selected in this study. Indications for PCI were objective evidence of myocardial ischemia (positive sign on stress test) or ischemic symptoms associated with significant angiographic stenosis (\> 75% stenosis). Patients who underwent haemodialysis were excluded, and fasting blood specimens were sampled in the morning prior to PCI. The patients\' demographic data, clinical features, laboratory tests, medications, angiographic and procedural information during hospitalisation were recorded.

2.2. Classification of RDW {#s2b}
--------------------------

Based on the preoperative median of RDW (12.3%), the patients were divided into two groups: the high RDW group (RDW ≥ 12.3) and the low RDW group (RDW \< 12.3).

2.3. Data source and clinical outcomes {#s2c}
--------------------------------------

Research-related original data were collected from the hospital\'s standard medical records. Laboratory tests and ECG data included records from the time of admission to the time prior to procedure. Data input and follow-up were all completed by cardiologists. Clinic service or telephone follow-up was performed according to a pre-designed questionnaire. The follow-up data were input into a unified form and then encoded into the computer database. The endpoint of this study was the occurrence of all-cause mortality after PCI. The mean follow-up time was 527 days, and the follow-up rate was 92.1%.

2.4. Statistical analysis {#s2d}
-------------------------

Continuous variables were presented as the mean and standard deviation. Inter-group comparison of continuous variables was performed using the Student\'s *t*-test or the Mann-Whitney *U*-test, whereas categorical variables were analysed using chi-square test or Fisher\'s exact test. Kaplan-Meier curves were constructed to compare cumulative survival between the two groups using the log-rank test. Cox regression equation was used to statistically analyse the relevant factors affecting all-cause mortality. Univariate model included the following variables: high RDW, age, gender, hypertension, diabetes, current smoking, family history of CAD, previous stroke, previous myocardial infarction, previous PCI, ST segment elevation myocardial infarction (STEMI), left ventricular ejection fraction (LVEF), hemoglobin, estimated glomerular filtration rate (eGFR), total cholesterol, low density lipoprotein cholesterol (LDL-C), triglyceride, multivessel disease, number of PCI vessels and baseline medications. As covariates for adjustment, those factors were chosen which were found to have a *P*-value lower than 0.2 in univariate analyses of death. The hazard ratio (HR) and 95% confidence interval (CI) of each relevant factor were calculated. All statistical test were two-tailed, statistical significance was set at *P *\< 0.05. All data were analysed using SPSS 13.0 statistical software.

3. Results {#s3}
==========

3.1. Baseline characteristics {#s3a}
-----------------------------

The baseline clinical characteristics are shown in [Table 1](#jgc-12-01-017-t01){ref-type="table"}. The mean age was 68.1 years old and 33.8% of patients were female. The high RDW group was more often accompanied with diabetes, and the proportion of female patients was higher than that of the low RDW group. Patients with high RDW had lower hemoglobin level. No significant difference was found in age, body mass index (BMI), hypertension, current smoking, family history of CAD, previous stroke, previous myocardial infarction, previous PCI, clinical presentation, systolic blood pressure, diastolic blood pressure, LVEF, white blood cells, haematocrit, eGFR, total cholesterol, LDL-C, triglyceride, fasting glucose, number of diseased vessels and number of PCI vessels between the two groups. There were no significant differences in baseline medications between the two groups ([Table 2](#jgc-12-01-017-t02){ref-type="table"}).

###### Baseline characteristics.

                                     RDW \< 12.3 (*n* = 899)   RDW ≥ 12.3 (*n* = 992)   *P* value
  --------------------------------- ------------------------- ------------------------ -----------
  Age, yrs                                 67.8 ± 5.3                68.5 ± 5.4           0.644
  Female                                   276 (30.7)                363 (36.6)           0.007
  BMI, kg/m^2^                             25.6 ± 3.2                25.4 ± 3.1           0.573
  Hypertension                             604 (67.2)                681 (68.6)           0.496
  Diabetes                                 210 (23.4)                289 (29.1)           0.004
  Current smoking                          421 (46.8)                441 (44.5)           0.301
  Family history of CAD                     33 (3.7)                  40 (4.0)            0.684
  Previous stroke                           94 (10.5)                121 (12.2)           0.234
  Previous myocardial infarction           159 (17.7)                186 (18.8)           0.550
  Previous PCI                              81 (9.0)                 104 (10.5)           0.281
  Clinical presentation                                                                
  STEMI                                    160 (17.8)                170 (17.1)           0.706
  NSTEMI                                    47 (5.2)                  47 (4.7)            0.624
  Unstable angina                          531 (59.1)                586 (59.1)           0.998
  Stable angina                            161 (17.9)                189 (19.1)           0.523
  Systolic pressure, mmHg                 131.6 ± 20.7              132.0 ± 20.5          0.515
  Diastolic pressure, mmHg                 77.3 ± 10.6              77.6 ± 10.6           0.867
  LVEF, %                                  61.5 ± 11.2              59.9 ± 11.4           0.953
  WBC, 10^9^/L                              7.2 ± 2.2                7.2 ± 2.1            0.101
  HCT, %                                    38.1 ±4.1                 41.2±3.8            0.061
  Hemoglobin, g/L                         136.4 ± 15.6              132.4 ± 16.6         \<0.001
  eGFR, mL · min^−1^ · 1.73 m^−2^          80.4 ± 27.3              79.2 ± 23.2           0.206
  Total cholesterol, mmol/L                4.62 ± 0.97              4.66 ± 1.03           0.369
  LDL-C, mmol/L                            2.69 ± 0.80              2.68 ± 0.79           0.914
  Triglyceride, mmol/L                     1.82 ± 1.17              1.82 ± 1.14           0.752
  Glucose, mmol/L                          5.93 ± 2.01              6.08 ± 2.20           0.050
  Number of diseased vessels                                                           
   1-vessel disease                        332 (36.9)                370 (37.3)           0.868
   2-vessel disease                        321 (35.7)                364 (36.7)           0.656
   3-vessel disease                        246 (27.4)                258 (26.0)           0.506
  Number of PCI vessels                     1.5 ± 0.6                1.4 ± 0.6            0.469

Data are presented as mean ± SD or *n* (%). BMI: body mass index; CAD: coronary artery disease; eGFR: estimated glomerular filtration rate; HCT: haematocrit; LDL-C: Low density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; RDW: red blood cell distribution width; STEMI: ST segment elevation myocardial infarction; WBC: white blood cells.

###### Baseline medication.

                  RDW \< 12.3 (*n* = 899)   RDW ≥ 12.3 (*n* = 992)   *P* value
  -------------- ------------------------- ------------------------ -----------
  DAPT                  888 (98.8)                973 (98.1)           0.229
  Βeta-blocker          764 (85.0)                870 (87.7)           0.085
  Statins               782 (87.0)                838 (84.5)           0.120
  ACEI/ARB              585 (65.1)                646 (65.1)           0.982

Data are presented as *n* (%). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; DAPT: dual antiplatelet therapy; RDW: red blood cell distribution width.

3.2. Clinical outcomes {#s3b}
----------------------

The mean follow-up period was 527 days, and the follow-up rate was 92.1%. During the follow up period, 61 patients died (43 cases in the high RDW group and 18 cases in the low RDW group). The mortality of the high RDW group was significantly higher than that of the low RDW group (4.3% *vs*. 2.0%, *P* = 0.004). Results of univariate analyses for all-cause death are shown in [Table 3](#jgc-12-01-017-t03){ref-type="table"}. In multivariate Cox proportional hazards modeling, high RDW was significantly associated with an increased incidence of all-cause death (HR: 2.301, 95%CI: 1.106--4.785, *P* = 0.026) ([Table 4](#jgc-12-01-017-t04){ref-type="table"}). The cumulative incidence of all-cause death was significantly higher in the high RDW group than in the low RDW group (*P* = 0.009, [Figure 1](#jgc-12-01-017-g001){ref-type="fig"}).

4. Discussion {#s4}
=============

Two conclusions could be drawn from the results of this study. Firstly, the patients with increased RDW were more often accompanied with diabetes, and the proportion of females was higher, had lower hemoglobin level. Secondly, after adjusting other factors, the increase in RDW was the independent predictor for the elevated mortality of elderly CAD patients after elective PCI, and the postoperative mortality of the high RDW group was almost 2.2 times higher than that of the low RDW group. The similar conclusion of the study also found in other studies. Considering that RDW detection is simple, easy and comes with no additional costs, this method could become a new indicator for the prognostic evaluation and risk stratification of elderly CAD patients.

###### Univariate analysis for all--cause mortality.

                                       HR        95%CI       *P* value
  ---------------------------------- ------- -------------- -----------
  High RDW                            2.052   1.182--3.561     0.011
  Age                                 1.053   1.007--1.101     0.023
  Gender (female)                     1.468   0.884--2.439     0.138
  Hypertension                        1.443   0.861--2.420     0.164
  Diabetes                            1.883   1.279--2.772     0.001
  Previous stroke                     1.197   0.569--2.518     0.635
  Previous myocardial infarction      1.200   0.650--2.215     0.559
  Previous PCI                        0.487   0.153--1.556     0.225
  Current smoking                     1.069   0.869--1.316     0.529
  Family history of CAD               1.329   0.416--4.250     0.631
  STEMI                               1.551   1.097--2.193     0.013
  LVEF                                0.974   0.955--0.995     0.014
  Hemoglobin                          0.973   0.959--0.988    \<0.001
  eGFR (mL · min^−1^ · 1.73 m^−2^)    0.977   0.964--0.989    \<0.001
  Total Cholesterol                   1.003   0.997--1.010     0.305
  LDL--C                              1.004   0.996--1.012     0.341
  Triglyceride                        0.999   0.996--1.003     0.726
  Multivessel disease                 1.709   1.235--2.366     0.001
  Number of PCI vessels               1.327   0.935--1.883     0.114
  DAPT                                0.877   0.221--6.328     0.896
  Use of β--blocker                   0.550   0.298--1.016     0.056
  Use of statins                      0.677   0.360--1.272     0.225
  Use of ACEI/ARB                     0.898   0.485--1.666     0.734

ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; LDL--C: Low density lipoprotein cholesterol; PCI: percutaneous coronary intervention; RDW: red blood cell distribution width; STEMI: ST segment elevation myocardial infarction.
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###### Multivariate analysis for all-cause mortality.

                          HR        95%CI       *P* value
  --------------------- ------- -------------- -----------
  Diabetes               2.311   1.392--3.837     0.001
  High RDW               2.301   1.106--4.785     0.026
  eGFR                   0.971   0.955--0.987   \< 0.001
  Multivessel disease    1.916   1.233--2.977     0.004

RDW: red blood cell distribution width; eGFR: estimated glomerular filtration rate.

Previous studies suggested that the increase in RDW can lead to increased mortality after PCI. Osadnik, *et al*.[@b14] enrolled 2550 cases of stable CAD patients who underwent PCI treatment. Based on the RDW levels at baseline, the patients were divided into four groups; the 2.5 years follow-up found that the corrected risk of death of the group with the highest RDW (≥ 14.1%) was fourfold than that of the group with the lowest RDW (\< 13.1%) (17.1% *vs*. 4.3%, *P* \< 0.0001). Tsuboi, *et al*.[@b15] investigated 560 stable CAD cases who had underwent PCI treatment and were accompanied with diabetes, among which 322 cases were aged \> 65 years old, and the 3.9 years follow-up found that the death risk rate of the high RDW group (13.3%--14.2%) was higher than that of the low RDW group (12.4%-- 12.9%, HR: 2.56, 95%CI: 1.12--6.62, *P* = 0.025).

Considering that the above subjects not only included patients aged \> 65 years old, the relationship between RDW and prognosis of elderly PCI patient remains unclear. The current study analysed a large sample of PCI patients aged ≥ 65 years old, and the high RDW group had a higher ratio of accompanying diabetes and female proportion, lower hemoglobin level. Many clinical studies showed that diabetes and low hemoglobin are independent predictors of poor prognosis for CAD patients after PCI.[@b16]--[@b19] Poor clinical outcomes of elderly diabetic patients are caused by multifaceted reasons, including atherosclerotic overloading, microvascular disease, prothrombotic state, excessive intimal hyperplasia, vascular inflammation, organ dysfunction and several other complications.[@b20]--[@b26] Some studies suggested that more adverse events occur in females than those in males after PCI, whereas other studies demonstrated that the incidence of adverse events has no gender differences.[@b27]--[@b31] After adjusting the related factors, the increase in RDW was an independent predictor for the increased mortality of elderly CAD patients after PCI.

The exact mechanism of the relationship between RDW and prognosis of cardiovascular diseases remains unclear. Data analysis of the America third national health and nutrition examination survey demonstrated that the C-reactive protein (CRP), fibrinogen level and white blood cell count were closely related to increasing RDW.[@b32] Lippi, *et al*.[@b33] discovered the relationship between high RDW and elevated inflammatory markers, which involved the association with the erythrocyte sedimentation rate and CRP, and this contact was independent from other concomitant diseases. When the blood diseases were excluded, this contact was also present. The CRP is an independent risk factor for CAD, and elevated levels of CRP are positively correlated with the incidence of adverse cardiovascular events.[@b34]--[@b36] CRP as a well-established biomarker of inflammation, has been available and useful for predicting future cardiovascular events in clinical practice. Studies showed that the elevated neutral/lymphocyte ratio, which is a direct indicator of inflammation, is highly correlated with the RDW level; therefore, RDW can be considered an inflammatory factor.[@b37] As a classic inflammatory cytokine, IL-6 is closely related to the elevation of RDW.[@b38] IL-6 is a powerful inducer of hepcidin gene transcription; an increase in IL-6 can reduce iron and result in increased RDW.[@b39] IL-6 is a multifunctional cytokine that plays an important role in the process of vascular injury in CAD, and has become an important marker for the stability of coronary atherosclerotic plaques, which are mainly developed by promoting platelet aggregation, enhancing the expression of reactive protein and fibrinogen and adjusting the expression of other inflammatory factors; thus, IL-6 is involved in the inflammatory process of unstable plaques.[@b40] The predictive roles of RDW in the prognosis of cardiovascular diseases might reflect the predictive roles of inflammation for the same prognosis.

4.1. Study limitations {#s4a}
----------------------

Some limitation of the present study must be considered. This was a single center, retrospective study. Residual confounding factors possibly affected the results, in addition to the lack of serum iron, folic acid, VitB12 status. Another limitation is that only intermediate-term follow-up results are available. Long-term follow-up is required to further verify the findings. Despite these limitations, the advantages of this study were its large sample size, detailed clinical data and laboratory indicators.

4.2. Conclusions {#s4b}
----------------

In conclusion, the present study demonstrated that high RDW is a predictive factor for all-cause mortality in elderly CAD patients after elective PCI. RDW had the potential to become a new indicator in prognostic evaluation and risk stratification of the elderly patients with coronary artery disease.
